Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288138 · ClinicalTrials.gov registry record · Phase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, sponsored by Eccogene.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07288138: Recruiting Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, sponsored by Eccogene.
NCT07288138 is a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis that is actively recruiting participants, run by Eccogene. The registered enrollment target is 160 participants, below the 389-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07288138, a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, is actively recruiting participants, sponsored by Eccogene.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ECC4703
- DRUG ECC0509
Study Locations (20)
Florida
- Synergy Healthcare - Bradenton
- Synergy Healthcare - Bradenton
- Health Awareness, Inc. - Jupiter
- Floridian Clinical Research, LLC - Miami Lakes
- Ocala GI Research - Ocala
- Progressive Medical Research - Port Orange
- ClinCloud, LLC - Viera
Arizona
- Arizona Liver Health - Chandler
- Arizona Liver Health - Peoria - Peoria
- Adobe Clinical Research, LLC - Tucson
- Arizona Liver Health - Tucson - Tucson
Louisiana
- Tandem Clinical Research - Covington
- Tandem Clinical Research - Houma
- Tandem Clinical Research GI, LLC - Marrero
Arkansas
- Arkansas Gastroenterology, P.A - Little Rock
- ARcare Center for Clinical Research - Little Rock
California
- ARK Clinical Research - Fountain Valley - Fountain Valley
- Ark Clinical Research - Long Beach
Georgia
- Gastrointestinal Specialists of Georgia, PC - Marietta
Indiana
- Digestive Research Alliance of Michiana - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 2 |
What NCT07288138 shows while recruiting
NCT07288138 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Metabolic Dysfunction-associated Steatohepatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07288138 names 20 study sites across 7 states, led by Florida, Arizona, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07288138 about?
NCT07288138 is a clinical study titled "A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)". The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week...
What is the current status of trial NCT07288138?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-12-15. Estimated completion is 2026-10-30.
What conditions does trial NCT07288138 study?
This clinical trial studies the following conditions: Metabolic Dysfunction-associated Steatohepatitis.
What interventions are being tested in trial NCT07288138?
The interventions under investigation include: Placebo (DRUG), ECC4703 (DRUG), ECC0509 (DRUG).
Who is sponsoring clinical trial NCT07288138?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288138 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Dysfunction-associated Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
COMPLETED · Phase 2
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI